Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Where does immuno-oncology fit in the treatment landscape of TNBC?

Rebecca Dent • 29 Apr 2021
ESMO Breast 2021
Breast Cancer Antibodies Atezolizumab Carboplatin Nab-paclitaxel Paclitaxel Pembrolizumab
IMpassion030 IMpassion130 IMpassion131 KEYNOTE-522

Rebecca Dent, MD, FRCP, National Cancer Centre Singapore, Singapore, discusses the role of immuno-oncology in the treatment of triple-negative breast cancer (TNBC), in particular talking on the use of immune checkpoint inhibitors and the presence of biomarkers such as tumor infiltrating lymphocytes (TILs) and PD-L1. Prof. Dent outlines data from clinical trials including the IMpassion130 trial (NCT02425891) and the IMpassion131 trial (NCT03125902), commenting on the approval of atezolizumab plus nab-paclitaxel. Prof. Dent also talks on the KEYNOTE-522 (NCT03036488) trial and the IMpassion030 trial (NCT03498716). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

More from Rebecca Dent

Treating early-stage TNBC
5:53
Treating early-stage TNBC
Rebecca Dent • 29 Apr 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals